Lungs and breathing

127 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Lungs and breathing
Treatment and conditionWhere it standsTrials
16-hour PP for acute lung injuryTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
a wake prone positioning for respiratory distress syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
a wake prone positioning for respiratory insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Air cleaner for pulmonary disease, chronic obstructivePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anti Thymocyte Globulin + GM-CSF + Total Body Irradiation + ALEMTUZUMAB + RITUXIMAB + HUMAN IMMUNOGLOBULIN G + Cyclophosphamide + THIOTEPA + Mesna for lung diseases, interstitialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Apps for respiratory insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Apremilast for respiratory distress syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Apremilast for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atibuclimab for respiratory distress syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atibuclimab for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aviptadil for respiratory distress syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aviptadil for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Awake prone positioning for respiratory distress syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Awake prone positioning for respiratory insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Azithromycin for respiration disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Azithromycin for respiratory insufficiencyTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Azithromycin 250 mg x3/week (3 tablets/week) + Hydroxychloroquine + Prednisone for lung diseases, interstitialTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BC006 for idiopathic pulmonary fibrosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Belimumab for lung diseases, interstitialPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Belumosudil 200 mg QD for pulmonary fibrosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Benralizumab for pulmonary disease, chronic obstructivePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Berobenatide for dyspneaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bersiporocin for idiopathic pulmonary fibrosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CAL101 for idiopathic pulmonary fibrosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Caspofungin for lung diseases, interstitialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Caspofungin for respiratory aspirationPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cenicriviroc for respiratory distress syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cenicriviroc for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
clonal fetal MSCs for pulmonary disease, chronic obstructiveTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CM326 dose 1 + CM326 dose 2 for pulmonary disease, chronic obstructivePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine 0.5 mg for pulmonary fibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Control for respiration disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
COVID-19 CONVALESCENT PLASMA for lung diseases, interstitialTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Cpap for respiratory insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CPAP + Dexamethasone for respiratory insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Curcumin for laryngostenosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cyclosporine for respiratory distress syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyclosporine for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CYP Cocktail + ZIPALERTINIB for lung diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyproheptadine for respiratory distress syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cyproheptadine for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Depemokimab for pulmonary disease, chronic obstructivePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dexamethasone for bronchopulmonary dysplasiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Dexamethasone for respiratory insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Dexamethasone. Dart for bronchopulmonary dysplasiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DIAG723 for pulmonary arterial hypertensionPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dornase alfa for respiratory distress syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dornase alfa for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dry Powder Inhaler + inhaled mosliciguat for lung diseases, interstitialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
EIT-Group for respiratory distress syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ENDS (Vaporizer/e-cig) and smoking cessation counseling for lung diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ENDS (Vaporizer/e-cig) and smoking cessation counseling for respiration disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Epidural spinal cord stimulation for respiratory insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Exercise for respiration disordersTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Famotidine + Celecoxib for respiratory distress syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Famotidine + Celecoxib for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FAPi-46 GA-68 for pleural diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Favipiravir for respiration disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
GSK3862995B for bronchiectasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GSK5784283 for nasal polypsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
GSK5784283 for paranasal sinus diseasesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
HB0056 for idiopathic pulmonary fibrosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
HFA-152a + Norflurane for bronchial spasmPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hfno for respiratory insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
HFNO + Dexamethasone for respiratory insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
HSK44459 for idiopathic pulmonary fibrosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Hydroxychloroquine for respiratory distress syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hydroxychloroquine for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hydroxychloroquine + azithromycin + / - tocilizumab for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hydroxychloroquine Pill + Azithromycin Pill for respiratory distress syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hydroxychloroquine sulfate for lung diseasesTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Hydroxychloroquine Sulfate + Azythromycin for lung diseasesTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Ibuprofen for respiratory distress syndromeTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Icatibant for respiratory distress syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Icatibant for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Imatinib Mesylate for respiratory distress syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Imatinib Mesylate for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Intermittent prone positioning instructions for respiratory insufficiencyTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Ketoprofen for pneumothoraxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LEAF-4L6715 for respiratory distress syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Mechanical ventilation with the automated BVM compressor for respiratory insufficiencyTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Mefloquine for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mefloquine + azithromycin + / - tocilizumab for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
myTAP oral appliance plus mouth shield for mouth breathingTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Nalbuphine for chronic coughPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Narsoplimab for respiratory distress syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Narsoplimab for respiratory insufficiencyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nintedanib for epistaxisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Oral Appliances for mouth breathingTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Oxymetazoline for nasal obstructionPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab + lenvatinib for lung diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Petosemtamab for laryngeal diseasesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prolonged Proned Positioning for respiratory insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prone decubitus for respiratory distress syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prone Position for acute lung injuryTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prone Position for respiratory aspirationTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prone Position for respiratory distress syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
prone positioning for respiratory distress syndromeTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Prone Positioning (PP) for respiratory distress syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Prone Positioning (PP) for respiratory insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Proning for respiratory insufficiencyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Quality-of-Life Assessment + Questionnaire Administration + Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine for pulmonary disease, chronic obstructivePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rentosertib for idiopathic pulmonary fibrosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ROC-101 for lung diseases, interstitialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ROC-101 for pulmonary arterial hypertensionPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide for pulmonary disease, chronic obstructivePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sildenafil Citrate for dyspneaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sildenafil Citrate for pulmonary disease, chronic obstructivePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy + Volume Modulated Arc Therapy + NIVOLUMAB + IPILIMUMAB for laryngeal diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy + Volume Modulated Arc Therapy + NIVOLUMAB + IPILIMUMAB for lung diseases, interstitialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Solizmestrocel for bronchopulmonary dysplasiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Solizmestrocel for respiratory distress syndromePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Taladegib for idiopathic pulmonary fibrosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tozorakimab for pulmonary disease, chronic obstructivePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)6
TQC2731 injection for pulmonary disease, chronic obstructivePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Transporter Cocktail + ZIPALERTINIB for lung diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Treprostinil for pulmonary arterial hypertensionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Treprostinil for pulmonary disease, chronic obstructiveTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Treprostinil palmitil for pulmonary arterial hypertensionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tulisokibart for lung diseases, interstitialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
UC-MSC and Secretome for respiratory distress syndromePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 100 mg Tablet for laryngeal diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 100 mg Tablet for tracheal diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for laryngeal diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for tracheal diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Wharton's jelly derived Mesenchymal stem cells. for respiratory distress syndromeTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Zipalertinib for lung diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1